Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | JNJ-89402638 |
| Trade Name | |
| Synonyms | JNJ 89402638|JNJ89402638 |
| Drug Descriptions |
Limited information is currently available on JNJ-89402638, a putative bispecific antibody targeting ENPP3 and CD3 (Nov 2024). |
| DrugClasses | CD3 Antibody 123 ENPP3 Antibody 5 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + Fluorouracil + Irinotecan + JNJ-89402638 + Leucovorin | Bevacizumab Fluorouracil Irinotecan JNJ-89402638 Leucovorin | 0 | 1 |
| Bevacizumab + Fluorouracil + JNJ-89402638 + Leucovorin + Oxaliplatin | Bevacizumab Fluorouracil JNJ-89402638 Leucovorin Oxaliplatin | 0 | 1 |
| Bevacizumab + JNJ-89402638 | Bevacizumab JNJ-89402638 | 0 | 1 |
| JNJ-89402638 | JNJ-89402638 | 0 | 1 |